Anteris technologies yesterday announced that the first 5 patients have successfully been implanted with Anteris’s DurAVR Valve.
An additional 5 patients are planned for treatment in the first quarter of 2022 to conclude the study.
This is a massive step towards FDA approval as AVR’s technology shows:
- Avoids the need for open heart surgery
- AVR’s heart valve have shown no calcification over 10 years – therefore avoids repeat surgery, and allows younger patients to be treated
- Early signs from first 5 patients have shown DurAVR providing superior haemodynamics
- Commissural alignment, flow characteristics and haemodynamics were proven to be clinically significant
Ann: Five TAVR Patients Successfully Implanted With DurAVR Valve, page-48
-
- There are more pages in this discussion • 93 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.19 |
Change
-0.010(0.08%) |
Mkt cap ! $257.6M | |||
| Open | High | Low | Value | Volume |
| $12.19 | $12.20 | $11.60 | $173.1K | 14.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9 | $11.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.19 | 28 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |